Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Lab21's portfolio swells with new tests from deCODE

This article was originally published in Clinica

  • News
  • Joseph Harvey  

Executive Summary

UK diagnostics firm Lab21 and Icelandic biopharmaceutical company deCODE genetics have struck up a deal to make the latter’s DNA-based tests available in the UK and Ireland. Lab21 will now distribute deCODE’s CE-marked and FDA-approved tests for genetic predisposition of type 2 diabetes, myocardial infarction, atrial fibrillation, prostate cancer and glaucoma. This deal also allows Cambridge-based Lab21 to offer new tests as they emerge from deCODE’s pipeline, including one for the increased risk of oestrogen-positive breast cancer. Financial details of the deal were not disclosed.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

EU: Good News For IVDs And For Future Transparency Of Medtech Compliance

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time

At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use

See All
UsernamePublicRestriction

Register

MT041550

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By